Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lebrikizumab - Eli Lilly and Company

Next Previous
X
Search
Drug Profile

Lebrikizumab - Eli Lilly and Company

Alternative Names: DRM 06; EBGLYSS; LY 3650150; MILR-1444A;; MILR1444A; MILR1444Ab; RG 3637; RO 5490255; TNX 650

Latest Information Update: 18 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tanox
  • Developer Almirall S.A.; Chugai Pharmaceutical; Eli Lilly and Company; Genentech; Roche; Tanox
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antifibrotics; Antineoplastics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atopic dermatitis
  • Phase III Allergic rhinitis; Asthma; Idiopathic pulmonary fibrosis; Rhinosinusitis
  • Discontinued Chronic obstructive pulmonary disease; Hodgkin's disease

Most Recent Events

  • 13 Sep 2024 Registered for Atopic dermatitis (In adolescents, In the elderly, Treatment-experienced, In adults) in USA (SC)
  • 12 Sep 2024 Preregistration for Atopic dermatitis (In adolescents, In the elderly, Treatment-experienced, In adults) in USA before September 2024 (SC)
  • 22 Jul 2024 Launched for Atopic dermatitis (In adolescents, In the elderly, In adults) in United Kingdom (SC) prior to July 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top